Anzeige
Mehr »
Freitag, 27.06.2025 - Börsentäglich über 12.000 News
Blockbuster-Bohrergebnisse: Gold-Antimon-Fund in Nevada trifft geopolitischen Nerv
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1C9RN | ISIN: US53220K5048 | Ticker-Symbol: LGDN
Tradegate
26.06.25 | 15:47
98,50 Euro
-0,51 % -0,50
1-Jahres-Chart
LIGAND PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
LIGAND PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
99,0099,5011:56
98,5099,5011:11

Aktuelle News zur LIGAND PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
11.06.Ligand Pharmaceuticals: Ligand Announces 2025 Investor Day in New York City3
09.06.LIGAND PHARMACEUTICALS INC - 8-K, Current Report1
08.05.Ligand Pharmaceuticals sees 22% CAGR in royalty revenue through 20292
08.05.ROUNDUP: Ligand Pharmaceuticals Reiterates FY25 Outlook203WASHINGTON (dpa-AFX) - While reporting financial results for the first quarter on Thursday, biopharmaceutical company Ligand Pharmaceuticals, Inc. (LGND) reiterated its adjusted earnings and...
► Artikel lesen
08.05.Ligand Pharmaceuticals GAAP EPS of -$2.21, revenue of $45.3M1
08.05.LIGAND PHARMACEUTICALS INC - 8-K, Current Report2
07.05.Ligand Pharmaceuticals Q1 2025 Earnings Preview2
17.04.Ligand's Pelthos unit joins forces with Channel Therapeutics in merger centered on launch of molluscum gel Zelsuvmi1
LIGAND PHARMACEUTICALS Aktie jetzt für 0€ handeln
17.04.Ligand unit Pelthos to merge with Channel Therapeutics1
17.04.Ligand, Channel Therapeutics Agree To Combine Pelthos, LNHC With CHRO Merger Sub388WASHINGTON (dpa-AFX) - Ligand Pharmaceuticals Inc. (LGND) Thursday announced a definitive merger agreement with Channel Therapeutics Corp. (CHRO) to combine Ligand's wholly owned subsidiaries...
► Artikel lesen
17.04.LIGAND PHARMACEUTICALS INC - 8-K, Current Report3
17.04.Ligand Pharmaceuticals: Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics251Proposed transaction will raise $50 million in equity capital and enhance a publicly traded biopharmaceutical company focused on launching Pelthos' ZELSUVMI ZELSUVMI is an FDA-designated novel drug...
► Artikel lesen
10.04.Analyst Sees Big Upside In Ligand's Capital-Efficient Biotech Strategy2
10.04.This Ligand Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday2
09.04.Stifel starts Ligand Pharma stock with Buy, $143 target1
28.02.LIGAND PHARMACEUTICALS INC - 10-K, Annual Report-
28.02.Ligand Pharma stock target raised to $153 by RBC Capital3
28.02.Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q4 2024 Earnings Call Transcript1
27.02.Ligand Pharma Slips To Loss In Q4; Confirms FY25 Outlook - Update2
27.02.ROUNDUP: Ligand Pharma Slips To Loss In Q4; Confirms FY25 Outlook276WASHINGTON (dpa-AFX) - Biopharmaceutical company Ligand Pharmaceuticals, Inc. (LGND), while reporting a loss in its fourth quarter, compared to prior year's profit, on Thursday confirmed fiscal...
► Artikel lesen
Weiter >>
37 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1